e-therapeutics plc engages in drug discovery research activities in the United Kingdom. The company offers HepNet, a hepatocyte-focused computational platform that enables identification of novel gene targets, improves drug design, and increases automation; and GalOmic, RNA interference (RNAi) platform that generates potent and safe GalNAc-siRNA therapeutics to selectively silence novel disease-associated genes in hepatocytes. Its preclinical products are ETX-312 to treat metabolic dysfunction-associated steatohepatitis; and ETX-407 for the treatment of dry age-related macular degeneration. The company also develops ETX-148 for haemophilia; ETX-291 to treat cardiometabolic disease, ETX-258 for heart failure; and ETX-394 to treat metabolic dysfunction-associated steatohepatitis. e-therapeutics plc incorporated in 2001 and is based in London, the United Kingdom.